{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:58:30Z","timestamp":1791687510773,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ygyno.2020.10.034","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T02:00:49Z","timestamp":1605232849000},"page":"227-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study"],"prefix":"10.1016","volume":"160","author":[{"given":"Hanneke","family":"Poort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anny T.H.R.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Embree","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Dinardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna J.","family":"Arch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5S","key":"10.1016\/j.ygyno.2020.10.034_bb0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.6004\/jnccn.2018.0034","article-title":"New therapies for ovarian cancer","volume":"16","author":"Armstrong","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"2","key":"10.1016\/j.ygyno.2020.10.034_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2015.06.005","article-title":"Long-term mortality among women with epithelial ovarian cancer","volume":"138","author":"Dinkelspiel","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2020.10.034_bb0015","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.ygyno.2020.10.034_bb0020","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ygyno.2020.10.034_bb0025","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"issue":"suppl_1","key":"10.1016\/j.ygyno.2020.10.034_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","article-title":"Cancer-related fatigue: the scale of the problem","volume":"12","author":"Hofman","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0035","article-title":"Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life","author":"Poort","year":"2019","journal-title":"Palliat Support Care."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00917","article-title":"Niraparib maintenance treatment improves time without symptoms or toxicity (twist) versus routine surveillance in recurrent ovarian cancer: a twist analysis of the engot-ov16\/nova trial","author":"Matulonis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","author":"Basen-Engquist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2010.09.025","article-title":"A new index of priority symptoms in advanced ovarian cancer","author":"Jensen","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0055","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-related fatigue, version 2.2015","author":"Berger","year":"2015","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/1098214016630406","article-title":"Evaluating bang for the Buck: a cost-effectiveness comparison between individual interviews and focus groups based on thematic saturation levels","author":"Namey","year":"2016","journal-title":"Am. J. Eval."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0065","doi-asserted-by":"crossref","DOI":"10.1023\/A:1008900413113","article-title":"Measurement of fatigue in cancer patients: further validation of the fatigue symptom inventory","author":"Hann","year":"2000","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.ygyno.2020.10.034_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1008842517972","article-title":"Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory","volume":"7","author":"Hann","year":"1998","journal-title":"Qual. Life Res."},{"issue":"9","key":"10.1016\/j.ygyno.2020.10.034_bb0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual. Health Res."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0080","series-title":"Qualitative Research & Evaluation Methods","author":"Patton","year":"2014"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0085","article-title":"Patients\u2019 views about causes and preferences for the management of cancer-related fatigue-a case for non-congruence with the physicians?","author":"Luthy","year":"2011","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2020.10.034_bb0090","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0095","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0100","doi-asserted-by":"crossref","DOI":"10.1046\/j.1523-5394.2000.82007.x","article-title":"Cancer-related fatigue: suffering a different fatigue","author":"Holley","year":"2000","journal-title":"Cancer Pract."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/0269216307085183","article-title":"Fatigue in palliative care patients \u2013 an EAPC approach","author":"Radbruch","year":"2008","journal-title":"Palliat. Med."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0110","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.12-S1-1","article-title":"Cancer-related fatigue: causes, consequences, and management","author":"Morrow","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/00002820-198806000-00009","article-title":"Patients\u2019 descriptions of the influence of tiredness and weakness on self-care abilities","author":"Rhodes","year":"1988","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(197905)43:5<1613::AID-CNCR2820430508>3.0.CO;2-8","article-title":"Adjuvant chemotherapy for breast carcinoma: psychosocial implications","author":"Meyerowitz","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3989286","article-title":"Cancer related fatigue and quality of life in patients with advanced prostate Cancer undergoing chemotherapy","author":"Charalambous","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32927","article-title":"Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study","author":"Poort","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03107","article-title":"Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of Rucaparib maintenance treatment in patients with recurrent ovarian carcinoma","author":"Oza","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2006.09.013","article-title":"Feeling like a burden: exploring the perspectives of patients at the end of life","author":"McPherson","year":"2007","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/1474515118811960","article-title":"Illness identity: capturing the influence of illness on the person\u2019s sense of self","author":"Van Bulck","year":"2019","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0155","doi-asserted-by":"crossref","DOI":"10.1007\/s10880-018-9552-0","article-title":"Illness identity in adults with a chronic illness","author":"Oris","year":"2018","journal-title":"J. Clin. Psychol. Med. Settings"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2006.01.003","article-title":"Toward a trajectory of identity reconstruction in chronic fatigue syndrome\/myalgic encephalomyelitis: a longitudinal qualitative study","author":"Whitehead","year":"2006","journal-title":"Int. J. Nurs. Stud."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0165","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-psych-010416-044014","article-title":"Adjusting to chronic health conditions","author":"Helgeson","year":"2017","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/j.1533-8525.1995.tb00459.x","article-title":"The body, identity, and self: adapting to impairment","author":"Charmaz","year":"1995","journal-title":"Sociol. Q."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0175","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-2559","article-title":"Illness identity in adolescents and emerging adults with type 1 diabetes: introducing the illness identity questionnaire","author":"Oris","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2019.09.002","article-title":"Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial","author":"Poort","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.034_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32521","article-title":"Internet-assisted cognitive behavioral intervention for targeted therapy\u2013related fatigue in chronic myeloid leukemia: results from a pilot randomized trial","author":"Jim","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.10.034_bb0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","author":"Poveda","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820340567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820340567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:38Z","timestamp":1758772598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820340567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0090825820340567"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}